Key facts
- · Type: New offering first sale 2026-09-14 · Amount sold: $7.75M · Total offering: $38.96M · SEC filing
- · Type: New offering first sale 2025-05-14 · Amount sold: $0 · Total offering: $20M · SEC filing
- · Type: New offering first sale 2025-05-12 · Amount sold: $5.95M · Total offering: $5.95M · SEC filing
- · Type: New offering first sale 2025-02-25 · Amount sold: $1.28M · Total offering: $1.28M · SEC filing
SAN FRANCISCO, CALIFORNIA
Biotechnology
4
$14.98M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-09-29 | New offering first sale 2026-09-14 | $7.75M | $38.96M | details · SEC filing |
| 2025-05-28 | New offering first sale 2025-05-14 | $0 | $20M | SEC filing |
| 2025-05-27 | New offering first sale 2025-05-12 | $5.95M | $5.95M | SEC filing |
| 2025-03-07 | New offering first sale 2025-02-25 | $1.28M | $1.28M | SEC filing |
What do you want to do with GT Biopharma, Inc.?
Who to contact
- Michael Breen — Chief Executive Officer
- Alan Urban — Chief Financial Officer
- Charles Casamento — Director
- Hilary Kramer — Director
- David Mun-Gavin — Director
- Round: Form D filed 2026-09-29
- Amount sold: $7.75M
- Industry: Biotechnology
- Based: SAN FRANCISCO, CALIFORNIA
People listed
- Michael Breen — Chief Executive Officer
- Alan Urban — Chief Financial Officer
- Charles Casamento — Director
- Hilary Kramer — Director
- David Mun-Gavin — Director
- Filing: Form D filed 2026-09-29
- Amount sold: $7.75M
- Industry group: Biotechnology
- Based: SAN FRANCISCO, CALIFORNIA
- Entity type: Corporation
We'll show it in your MentionFox inbox when GT Biopharma, Inc. raises, hires or launches. No email unless you switch it on.
Watch GT Biopharma, Inc. →Want the whole picture on GT Biopharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on GT Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GT Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from GT Biopharma, Inc.'s own filings with the SEC. The people those filings name are on the team page.